Adimmune

• 2021-11-22

  Adimmune Receives TWD 300M License Fee for COVID-19 Candidate Vaccine

  Adimmune Corporation (TPE: 4142) announced on 23rd that it has signed a Licensing Agreement for

• 2021-11-10

  Boosted by Global Orders, Adimmune Q3 Revenue Hits a New High

  Adimmune Corporation (TPE: 4142) announced on 10th the revenue of the third quarter (Q3). Benef

• 2021-10-07

  Adimmune Delivers Strong Q3 Revenue Growth, Driven by Influenza Vaccine

  Adimmune Corporation (TPE: 4142) announced on the 6th that the revenue for September 2021 reach

• 2021-09-23

  Adimmune to Supply Influenza Vaccine Antigen to Russia, Central Asia, and Eastern Europe

  Adimmune Corporation (TPE: 4142) announced on 22nd it has signed a contract with Petrovax, a Ru

• 2021-09-13

  Adimmune’s Next-Generation COVID-19 Vaccine Receives Clinical Trial Approval from Indonesia

  Adimmune Corporation (TPE: 4142) announced on the 13th its COVID-19 vaccine candidate has recei

• 2021-09-09

  Adimmune’s August Revenue Grows 40% with A Boost from New Production Line Launch

  Adimmune Corporation (TPE 4142) announced the revenue for August 2021 at TWD 236 million, a 40.

• 2021-08-12

  Adimmune’s new production line receives GMP certification, at the ready to manufacture public tender seasonal influenza vaccines

  Adimmune Corporation (4142) announced on the 11th that its second fill & finish line has pa

• 2021-07-08

  Adimmune announced a planned overseas manufacturing site in Indonesia, launching its global expansion

  Adimmune Corporation (4142) announced today that its first overseas manufacturing site will be

• 2021-05-25

  Onward to Southeast Asia, Adimmune Corporation and Innovalues signed MOU

  Adimmune Corporation (4142) announced on the 25th that Adimmune Corporation, Enimmune Corp., an

• 2021-04-07

  Adimmune Corporation successfully bid for the procurement of public tender seasonal influenza vaccines, continues its global market expansion

  Taiwan Centers for Disease Control (CDC) of Ministry of Health and Welfare announced today that

• 2021-03-02

  Adimmune Corporation precisely predicted the WHO recommended strains of seasonal influenza virus to ensure

  World Health Organization (WHO) announced in late February the recommended seasonal influenza v

• 2021-02-17

  Adimmune Corporation is developing the next generation of COVID-19 vaccines, commencing clinical trial overseas

  Adimmune Corporation (4142) announced that in response to the emerging variants of SARS-CoV-2 a

• 2021-01-20

  Adimmune Corporation and Korean Pharma signed an agreement for international collaboration on biosimila

  Adimmune Corporation (4142) announced the signing of an agreement with SCD, a leading ophthalmi

• 2020-12-30

  Adimmune Biotech Corporation(4142) is determined and committed to continue developing the COVID-19 vaccine

  Adimmune Biotech Corporation pointed out, after receiving the government's official notificatio

• 2020-12-29

  Prepared for the international markets Adimmune Biotech Corporation appointed Dr. Chun Cheng Chen as the Chief Medical Officer

  Adimmune Biotech Corporation(4142) announced today, beginning January 2021 Dr. Chun

• 2020-09-11

  Adimmune COVID-19 Vaccine Production Team Welcomes JHL Biotech, Inc

  Adimmune Biotech Corporation(4142) announced today that it has signed a Master Service Agreemen

• 2020-08-27

  Adimmune Biotech Corporation’s COVID-19 vaccine entered the human clinical test phase. Taiwan’s unlocking from the epidemic is to be expected in the near future

  Adimmune Biotech Corporation’s(4142) COVID-19 vaccine entered Phase 1 human clinical test this

• 2020-07-14

  Adimmune Biotech Corporation signed a $4.2 billion syndicated loan agreement, the sufficient funds would invigorate the company’s future business expansion

  Adimmune Biotech Corporation(4142) secured a $4.2 billion syndicated loan today. Adimmune Chair

• 2020-06-22

  Adimmune Biotech Corporation applied permit for COVID-19 vaccine human clinical experiment

  Adimmune Biotech Corporation(4142) held its 2020 shareholders meeting today. In the meeting it

• 2020-06-09

  During a visit to Adimmune Biotech Corporation(4142), Executive Yuan Premier Cheng Chang Su expressed his high expectations for the company’s success in developing the COVID-19 vaccine

  Today, the Executive Yuan Premier Cheng Chang Su and his administrative team visited Adimmune B